STOCK TITAN

Crinetics (CRNX) grants RSUs and stock options to board director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Crinetics Pharmaceuticals director Caren Deardorf received new equity awards in the form of restricted stock units and stock options. She was granted 5,925 restricted stock units, representing the right to receive the same number of common shares, which vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, subject to her continued board service.

She was also granted stock options covering 9,730 shares of common stock at an exercise price of $35.87 per share, expiring on June 18, 2036, with the same vesting schedule. Following these awards, she directly holds 22,225 shares of common stock, in addition to the new option position.

Positive

  • None.

Negative

  • None.
Insider Deardorf Caren
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 9,730 $0.00 --
Grant/Award Common Stock 5,925 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 9,730 shares (Direct, null); Common Stock — 22,225 shares (Direct, null)
Footnotes (1)
  1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Restricted stock units granted 5,925 shares Equity award granted June 18, 2026
Stock options granted 9,730 options Right to buy common stock
Option exercise price $35.87 per share Stock option strike price
Option expiration date June 18, 2036 Option term end date
Shares held after RSU grant 22,225 shares Direct common stock holdings following transaction
restricted stock units financial
"involves the receipt of restricted stock units, which represent the right to receive shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"100% vesting on the earlier of (a) the first anniversary of the grant date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"Stock Option (Right to Buy) ... conversion_or_exercise_price: "35.8700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Deardorf Caren

(Last)(First)(Middle)
C/O CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026A5,925A$0(1)22,225D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$35.8706/18/2026A9,730 (2)06/18/2036Common Stock9,730$09,730D
Explanation of Responses:
1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
2. The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Remarks:
/s/ Tobin Schilke, as attorney-in-fact06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Caren Deardorf receive from Crinetics (CRNX)?

Caren Deardorf received 5,925 restricted stock units and stock options for 9,730 shares of Crinetics common stock. The options carry a $35.87 exercise price and expire June 18, 2036, providing equity compensation tied to her service as a director.

When do Caren Deardorf’s new Crinetics (CRNX) awards vest?

Both the restricted stock units and stock options vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual stockholder meeting. Vesting requires her continued service on Crinetics’ board through that vesting date.

What is the exercise price and term of Caren Deardorf’s Crinetics stock options?

The stock options cover 9,730 shares of Crinetics common stock at an exercise price of $35.87 per share. They expire on June 18, 2036 and follow the stated vesting schedule before becoming exercisable by the director.

How many Crinetics (CRNX) shares does Caren Deardorf hold after these awards?

After the grant of restricted stock units, Caren Deardorf directly holds 22,225 shares of Crinetics common stock. In addition, she holds stock options covering 9,730 underlying shares, which will vest and become exercisable under the award terms.

Are Caren Deardorf’s new Crinetics awards open-market purchases or compensation grants?

These transactions are compensation-related grants, not open-market purchases or sales. The Form 4 shows them with code “A” for grant, award, or other acquisition, reflecting restricted stock units and stock options tied to her board service and vesting conditions.